These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 29930098

  • 1. Microvascular abnormalities secondary to radiation therapy in neovascular age-related macular degeneration: findings from the INTREPID clinical trial.
    Freiberg FJ, Michels S, Muldrew A, Slakter J, O'Shaughnessy D, Czeszynski A, Danielson L, Jackson TL, Chakravarthy U.
    Br J Ophthalmol; 2019 Apr; 103(4):469-474. PubMed ID: 29930098
    [Abstract] [Full Text] [Related]

  • 2. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
    Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, O'Shaughnessy D, Gertner ME, Danielson L, Moshfeghi DM, INTREPID Study Group.
    Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
    [Abstract] [Full Text] [Related]

  • 3. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
    Jackson TL, Dugel PU, Bebchuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA, CABERNET Study Group.
    Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
    [Abstract] [Full Text] [Related]

  • 4. Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study.
    Jackson TL, Chakravarthy U, Slakter JS, Muldrew A, Shusterman EM, O'Shaughnessy D, Arnoldussen M, Gertner ME, Danielson L, Moshfeghi DM, INTREPID Study Group.
    Ophthalmology; 2015 Jan; 122(1):138-45. PubMed ID: 25208859
    [Abstract] [Full Text] [Related]

  • 5. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I, Oshima Y, Shiose S, Kano K, Nakao S, Kaizu Y, Yoshida S, Ishibashi T, Sonoda KH.
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [Abstract] [Full Text] [Related]

  • 6. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ.
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [Abstract] [Full Text] [Related]

  • 7. Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial.
    Jackson TL, Desai R, Simpson A, Neffendorf JE, Petrarca R, Smith K, Wittes J, Lewis C, Membrey L, Haynes R, Costen M, Steel DH, Muldrew A, Chakravarthy U, Macular Epiretinal Brachytherapy versus Ranibizumab (Lucentis) Only Treatment (MERLOT) Study Group.
    Ophthalmology; 2016 Jun; 123(6):1287-96. PubMed ID: 27086023
    [Abstract] [Full Text] [Related]

  • 8. Changes in Peripapillary Nerve Fiber Layer Thickness after Adjuvant Stereotactic Radiotherapy in Patients with Neovascular Age-Related Macular Degeneration.
    Ranjbar M, Kurz M, Holzhey A, Rades D, Grisanti S.
    Curr Eye Res; 2017 Dec; 42(12):1698-1706. PubMed ID: 28937877
    [Abstract] [Full Text] [Related]

  • 9. Microvascular abnormalities and long-term efficacy after stereotactic radiotherapy under continued intravitreal anti-VEGF treatment for neovascular AMD.
    Hatz K, Zimmermann F, Lazaridis E, Kardamakis D, Guichard M, Türksever C, Pruente C, Schmidt-Erfurth UM, Gerendas BS.
    Br J Ophthalmol; 2022 Mar; 106(3):415-421. PubMed ID: 33355151
    [Abstract] [Full Text] [Related]

  • 10. Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study.
    Silva R, Cachulo ML, Fonseca P, Bernardes R, Nunes S, Vilhena N, Faria de Abreu JR.
    Ophthalmologica; 2011 Mar; 226(3):110-8. PubMed ID: 21822000
    [Abstract] [Full Text] [Related]

  • 11. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [Abstract] [Full Text] [Related]

  • 12. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C.
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [Abstract] [Full Text] [Related]

  • 13. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
    Christenbury JG, Phasukkijwatana N, Gilani F, Freund KB, Sadda S, Sarraf D.
    Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
    [Abstract] [Full Text] [Related]

  • 14. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).
    Dugel PU, Bebchuk JD, Nau J, Reichel E, Singer M, Barak A, Binder S, Jackson TL, CABERNET Study Group.
    Ophthalmology; 2013 Feb; 120(2):317-27. PubMed ID: 23174399
    [Abstract] [Full Text] [Related]

  • 15. Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration.
    Aurell S, Sjövall K, Paul A, Morén Å, Granstam E.
    Acta Ophthalmol; 2019 Aug; 97(5):519-524. PubMed ID: 30511374
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration.
    Kuehlewein L, Bansal M, Lenis TL, Iafe NA, Sadda SR, Bonini Filho MA, De Carlo TE, Waheed NK, Duker JS, Sarraf D.
    Am J Ophthalmol; 2015 Oct; 160(4):739-48.e2. PubMed ID: 26164826
    [Abstract] [Full Text] [Related]

  • 19. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Dolz-Marco R, Phasukkijwatana N, Sarraf D, Freund KB.
    Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.